ACS. Key statistics for prostate cancer. 2024. Available from: https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html#:~:text=About%201%20in%208%20men,to%20develop%20in%20older%20men.

WHO. World Health Organization Cancer Tomorrow. 2024. Available from: https://gco.iarc.fr/tomorrow/home.

El Fakiri M, Geis NM, Ayada N, Eder M, Eder AC. PSMA-targeting radiopharmaceuticals for prostate cancer therapy: recent developments and future perspectives. Cancers (Basel). 2021;13(16):3967.

Article  PubMed  Google Scholar 

Dathathri E, Isebia KT, Abali F, Lolkema MP, Martens JWM, Terstappen L, Bansal R. Liquid biopsy based circulating biomarkers in metastatic prostate cancer. Front Oncol. 2022;12:863472.

Article  CAS  PubMed  Google Scholar 

Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, Cho SY, Fanti S, Giesel FL, Goffin K, Haberkorn U, Jacene H, Koo PJ, Kopka K, Krause BJ, Lindenberg L, Marcus C, Mottaghy FM, Oprea-Lager DE, Osborne JR, Piert M, Rowe SP, Schöder H, Wan S, Wester H-J, Hope TA, Herrmann K. PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. European J Nucl Med Mol Imaging. 2023;50(5):1466–86.

Article  Google Scholar 

Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, Park CH, Beer TM, Armour A, Pérez-Contreras WJ, DeSilvio M, Kpamegan E, Gericke G, Messmann RA, Morris MJ, Krause BJ. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091–103.

Article  CAS  PubMed  Google Scholar 

Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, Özgüroğlu M, Ye D, Feyerabend S, Protheroe A, De Porre P, Kheoh T, Park YC, Todd MB, Chi KN. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352–60.

Article  CAS  PubMed  Google Scholar 

Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–97.

Article  CAS  PubMed  Google Scholar 

Wang X, Yang H, Hu X, Wang W, Yu X, Wang S, Zhang X, Liu L. Comparing the clinical efficacy and safety of abiraterone and enzalutamide in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. J Oncol Pharm Pract. 2021;27(3):614–22.

Article  CAS  PubMed  Google Scholar 

Ramnaraign B, Sartor O. PSMA-targeted radiopharmaceuticals in prostate cancer: current data and new trials. Oncologist. 2023;28(5):392–401.

Article  PubMed  Google Scholar 

Yang H, Zhang Y, Su D, Zhang Y, Chen Y. Treatment of multiple bone metastases of castration-resistant prostate cancer with 225 Ac-PSMA-617. Clin Nucl Med. 2023;48(12):1078–81.

Article  PubMed  Google Scholar 

Bashir H, Numair Younis M, Rehan Gul M. Nuclear medicine theranostics: perspective from Pakistan. Nucl Med Mol Imaging. 2019;53(1):38–41.

Article  PubMed  Google Scholar 

Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schäfers M, Essler M, Baum RP, Kulkarni HR, Schmidt M, Drzezga A, Bartenstein P, Pfestroff A, Luster M, Lützen U, Marx M, Prasad V, Brenner W, Heinzel A, Mottaghy FM, Ruf J, Meyer PT, Heuschkel M, Eveslage M, Bögemann M, Fendler WP, Krause BJ. German Multicenter Study Investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58(1):85–90.

Article  CAS  PubMed  Google Scholar 

Clemens K, Frederik LG, Melsa S, Martina B, Marcus B, Ali A-O, Walter M, Matthias E, Klaus K, Uwe H. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-Labeled PSMA-617. J Nucl Med. 2016;57(8):1170.

Article  Google Scholar 

Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, Iravani A, Kong G, Ravi Kumar A, Murphy DG, Eu P, Jackson P, Scalzo M, Williams SG, Sandhu S. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19(6):825–33.

Article  CAS  PubMed  Google Scholar 

Naeem Z, Zahra UB, Numair Younis M, Khan IU, Shahid A. Lutetium-177 prostate specific membrane antigen therapy in a patient with double malignancy and single functioning kidney: a case report. Cureus. 2023;15(3):e36938.

PubMed  Google Scholar 

Fallah J, Agrawal S, Gittleman H, Fiero MH, Subramaniam S, John C, Chen W, Ricks TK, Niu G, Fotenos A, Wang M, Chiang K, Pierce WF, Suzman DL, Tang S, Pazdur R, Amiri-Kordestani L, Ibrahim A, Kluetz PG. FDA approval summary: lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2023;29(9):1651–7.

Article  CAS  PubMed  Google Scholar 

Kim EE. Targeted molecular imaging. Korean J Radiol. 2003;4(4):201.

Article  PubMed  Google Scholar 

Kratochwil C, Fendler WP, Eiber M, Hofman MS, Emmett L, Calais J, Osborne JR, Iravani A, Koo P, Lindenberg L, Baum RP, Bozkurt MF, Delgado Bolton RC, Ezziddin S, Forrer F, Hicks RJ, Hope TA, Kabasakal L, Konijnenberg M, Kopka K, Lassmann M, Mottaghy FM, Oyen WJG, Rahbar K, Schoder H, Virgolini I, Bodei L, Fanti S, Haberkorn U, Hermann K. Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT). European Journal of Nuclear Medicine and Molecular Imaging. 2023;50(9):2830–45.

Article  CAS  PubMed  Google Scholar 

Ahmadzadehfar H, Eppard E, Kürpig S, Fimmers R, Yordanova A, Schlenkhoff CD, Gärtner F, Rogenhofer S, Essler M. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget. 2016;7(11):12477–88.

Article  PubMed  PubMed Central  Google Scholar 

Pastorino S, Riondato M, Uccelli L, Giovacchini G, Giovannini E, Duce V, Ciarmiello A. Toward the discovery and development of PSMA targeted inhibitors for nuclear medicine applications. Curr Radiopharm. 2020;13(1):63–79.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Taylor RD, Jewsbury PJ, Essex JW. A review of protein-small molecule docking methods. J Comput Aided Mol Des. 2002;16:151–66.

Article  CAS  PubMed  Google Scholar 

Ashfaq W, Rehman K, Shahid A, Younis MN. SUV max as predictor of metastatic disease on 18 F-FDG PET-CT in hepatocellular carcinoma. J Coll Phys Surg Pak. 2024;34(4):394–9.

Google Scholar 

Khreish F, Ghazal Z, Marlowe RJ, Rosar F, Sabet A, Maus S, Linxweiler J, Bartholomä M, Ezziddin S. 177Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: initial 254-patient results from a prospective registry (REALITY Study). Eur J Nucl Med Mol Imaging. 2022;49(3):1075–85.

Article  CAS  PubMed  Google Scholar 

Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Ng S. [177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. The Lancet. 2021;397(10276):797–804.

Article  CAS  Google Scholar 

eviQ. Haematological toxicity. 2017. Available from: https://www.eviq.org.au/dose-mod-gradings/standard-ctcae/haematological-toxicity

Derlin T, Riethdorf S, Schumacher U, Lafos M, Peine S, Coith C, Ross TL, Pantel K, Bengel FM. PSMA-heterogeneity in metastatic castration-resistant prostate cancer: circulating tumor cells, metastatic tumor burden, and response to targeted radioligand therapy. Prostate. 2023;83(11):1076–88.

Article  CAS  PubMed  Google Scholar 

Christiane S, Jingjing Z, Harshad RK, Xiaoyuan C, Dirk M, Richard PB. Prostate-specific membrane antigen radioligand therapy using 177Lu-PSMA I&T and 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: comparison of safety, biodistribution, and dosimetry. J Nucl Med. 2022;63(8):1199–207.

Article  Google Scholar 

Gourni E, Henriksen G. Metal-based PSMA radioligands. Molecules. 2017;22(4):523.

Article  PubMed  Google Scholar 

Heidegger I, Kesch C, Kretschmer A, Tsaur I, Ceci F, Valerio M, Tilki D, Marra G, Preisser F, Fankhauser C, Zattoni F, Chiu P, Puche-Sanz I, Olivier J, Bergh R, Kasivisvanathan V, Pircher A, Virgolini I, Gandaglia G. Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer—a state of the art review. Ther Adv Med Oncol. 2022;14:175883592210819.

Article  Google Scholar